ArticleiScience2025
Efficient and accurate non-invasive tumor monitoring and diagnosis by interpretable deep learning.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Narrative review: clinical application and challenges of circulating tumor DNA in treatment response evaluation and prognostic prediction for esophageal cancer.Journal of thoracic disease · 2026Review
- Protocol for non-invasive tumor monitoring and diagnosis based on interpretable deep learning.STAR protocols · 2026Article
- From multi-omics to deep learning: advances in cfDNA-based liquid biopsy for multi-cancer screening.Biomarker research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detecting tumor-specific DNA methylation in circulating tumor DNA (ctDNA) offers a non-invasive method for tumor detection. The primary challenge lies in identifying the extremely low abundance of ctDNA in cell-free blood plasma (cfDNA). In this study, we present Oncoder, an interpretable deep learning-based tool for economical and accurate non-invasive tumor monitoring and diagnosis. Unlike other methods, Oncoder learns scientifically sound reference methylation atlases from patient blood to provide additional diagnostic insights, fostering trust among clinicians and patients, and continuously improves its accuracy through iterative learning. In simulations, Oncoder reduced prediction errors of tumor signals in blood by at least 30% compared to existing methods and showed the highest prediction correlation, indicating more accurate tumor progression monitoring. We also evaluated Oncoder's performance in various real-world applications. Oncoder sensitively detected changes in ctDNA levels during tumor development and treatment and exhibited superior diagnostic potential even in the earliest stages of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.